Skip to main content
NCBI home page
Springer logoLink to Springer
. 2018 Nov 22;22(3):526. doi: 10.1007/s10120-018-0900-4

Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer

Shusuke Yagi 1, Takeru Wakatsuki 1,✉, Noriko Yamamoto 2, Keisho Chin 1, Daisuke Takahari 1, Mariko Ogura 1, Takashi Ichimura 1, Izuma Nakayama 1, Hiroki Osumi 1, Eiji Shinozaki 1, Mitsukuni Suenaga 1, Junko Fujisaki 1, Yuichi Ishikawa 1, Kensei Yamaguchi 1, Ken Namikawa 1, Yusuke Horiuchi 1
PMCID: PMC6476830  PMID: 30467737

Correction to: Gastric Cancer 10.1007/s10120-018-0887-x

In the original publication of this article, Table 4 was published incorrectly. The correct Table 4 is given below.

Table 4.

Comparison survivals between surgical specimens and biopsy specimens

Biopsy specimens Surgical specimens
mPFS
 Homo-HER2 10.8 (95% CI 6.9–19.4) 20.0 (95% CI 17.8–22.2)
 Hetero-HER2 6.1 (95% CI 5.3–8.2) 6.0 (95% CI 2.3–9.7)
mOS
 Homo-HER2 29.3 (95% CI 20.5–NR) NR
 Hetero-HER2 14.4 (95% CI 11.4–17.8) 14.0 (95% CI 11.9–16.1)
Open in a new tab

mPFS median progression-free survival, mOS median overall survival, NR not reached, Homo-HER2 homogeneously HER2 positive, Hetero-HER2 heterogeneously HER2 positive

The original article has been corrected. Publisher sincerely apologizes for the error.

Contributor Information

Takeru Wakatsuki, Phone: +81-3-3520-0111, Email: takeru.wakatsuki@jfcr.or.jp.

Ken Namikawa, Email: ken.namikawa@jfcr.or.jp.

Yusuke Horiuchi, Email: yusuke.horiuchi@jfcr.or.jp.

Articles from Gastric Cancer are provided here courtesy of Springer

RESOURCES